Conclusions

COPD patients with no history of exacerbations initiating TIO+OLO had significantly lower annual severe exacerbations and pneumonia rates versus those initiating TT.
Using baseline exacerbation history as a proxy for COPD severity, these real-world findings support GOLD prescribing recommendations restricting TT for the most severe COPD patients.